AAD 2018: Treatment with Lilly's Taltz(R) (ixekizumab) Resulted in Improvement in Impact of Genital Psoriasis on Sexual Activity
Reductions in the impact of genital psoriasis on sexual activity seen as early as one week
INDIANAPOLIS, Feb. 19, 2018 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) announced today that patients with moderate-to-severe ... Biopharmaceuticals, Dermatology Eli Lilly, Taltz, ixekizumab, genital psoriasis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news